<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335136">
  <stage>Registered</stage>
  <submitdate>8/02/2010</submitdate>
  <approvaldate>12/02/2010</approvaldate>
  <actrnumber>ACTRN12610000143022</actrnumber>
  <trial_identification>
    <studytitle>Ascending dose of 40 % Lidocaine Gel applied to patients with Postherpetic Neuralgia.</studytitle>
    <scientifictitle>A Phase I/II Pilot Single Ascending Dose, Randomized, Double Blind, Placebo Controlled Study to Evaluate Two Topically Applied 40% Lidocaine Gel Formulations in Patients With Postherpetic Neuralgia (Protocol Number:  LID-001)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Herpes Zoster (shingle)</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ascending dose of 40% Lidocaine gel in two formulations. 
Cohort 1a and 1b will receive one dose of 0.125 ml of gel applied by hand to the skin
Cohort 2a and 2b will recieve one dose of 0.250 mlof gel applied by hand.
Cohort 3a and 3b will recieve one dose of 0.500 ml of gel applied by hand.</interventions>
    <comparator>Placebo gel.  This Gel is similar to the active formulation however the active component is removed.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and Tolerabilty of two formulations of 40% Lidocaine gel at 0.125ml 0.250ml and 0.500 ml will be assesed on the basis of adverse events reported, vital signs and patient quesitonaire.
The potential adverse events expected in this study are: burning, swelling, redness, irratation, bruising of the skin.  These site reaction are generally mild and resolve without treatment with in a few minutes to hours.</outcome>
      <timepoint>Patients will be continuously monitered while they are on the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To asses the affect of two formulations of 40% Lidocaine gel.</outcome>
      <timepoint>Patients will be asked to rate there pain intensity at 30 minutes, 1,2,4,6,8,12,16 and 24 hours post dose. The patients will do this by answering a qustionnaire. 
Patients will also have a brush evoked pain assesment performed at 1,2,4,8,12,24 hours post dose. This assesment is performed by a doctor using a study specifc brush</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male or Female patients with a diagnosis of Herpes Zoster (shingles) with Posthepetic Neuralgia.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Any significant unstable medical condition, allergic reaction or hypersensitivity to Lidocaine.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Nucleus Network</primarysponsorname>
    <primarysponsoraddress>Level 5, AMREP Precinct 
89 Commercail Road, 
Melbourne, Victoria  3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Arcion Therapeutics, Inc</fundingname>
      <fundingaddress>2400 Boston Street, Suite 300 Baltimore, MD 21224</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Post Therpetic Neuralgia is the pain that persist after the shingles rash has gone. The purpose of this sutdy is to research the use of Lignocaine in treating this pain.  There will be no long term benifits from particpating in this trial as the patients will only recieve one dose of study drug.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Research and Ethcis Unit</ethicname>
      <ethicaddress>The Alfred Hospital,  Commercial Road,23 Melbourne, Vicoria.</ethicaddress>
      <ethicapprovaldate>23/12/2009</ethicapprovaldate>
      <hrec>1/09/0452</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associoate Prof Peter Hodsman</name>
      <address>Centre for Clinical Studies. 
5th Floor Burnet Tower, AMREP Precinct, 89 Commercail Road, Melbourne, Victoria, 3004</address>
      <phone>61 3 90768900</phone>
      <fax>61 3 90768911</fax>
      <email>p.hodsman@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mary Franich</name>
      <address>Centre for Clinical Studies. 
5th Floor Burnet Tower, AMREP Precinct, 89 Commercail Road, Melbourne, Victoria, 3004</address>
      <phone>1800 243 733</phone>
      <fax>61 3 90768911</fax>
      <email>contactus@centreforclinicalstudies.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bianca Scott</name>
      <address>Centre for Clinical Studies. 
5th Floor Burnet Tower, AMREP Precinct, 89 Commercail Road, Melbourne, Victoria, 3004</address>
      <phone>61 3 90768925</phone>
      <fax>61 3 90768911</fax>
      <email>b.scott@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>